Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...

Pfizer in ​December had warned that the next few years would be bumpy, ‌beginning with 2026, ‍due to lower sales of its COVID ...

Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its ...

Merck MRK continues to face persistent challenges with sales of its second-largest product, Gardasil, which is a vaccine used ...

With an FDA accelerated approval in November 2023, Ixchiq became the world’s first shot for chikungunya. Its retreat leaves Bavarian Nordic’s Vimkunya the only available chikungunya vaccine in the U.S ...

Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. are creating uncertainty across the pharmaceutical sector, dampening investor confidence and raising concerns among ...

Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical ...

U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to ...

Pfizer increased prices for 72 products, including COVID shots. Merck raised the price on 18 of its products, including ...